First EU-Authorised Treatment for MCT8 Deficiency (Allan-Herndon-Dudley)

Emcitate (tiratricol) is a T3 analogue (thyroid hormone–related medicine) supplied as 350 microgram dispersible tablets mixed in water and given by mouth or feeding tube. On 12 February 2025, the European Commission granted a marketing authorisation valid throughout the EU for Emcitate to treat peripheral thyrotoxicosis in people with MCT8 deficiency (Allan-Herndon-Dudley syndrome), from birth. EMA lists the EC decision as 12 February 2025; some company materials cite 13 February — this article uses the EMA date. EMA framing at authorisation: there was no previously authorised EU treatment for this peripheral thyrotoxicosis. The medicine is a hybrid of the French reference product Téatrois (same active substance; different tablet form).

Distinct path — not this carton (fact-only): Supportive developmental care, tube feeding, seizure care, or cardiac monitoring alone are not this labelled Emcitate dispersible tablet. Other causes of hyperthyroidism (for example Graves’ disease) are contraindicated on the EU SmPC — Emcitate is not a general antithyroid drug. Compounded tiratricol / Triac products outside the Rare Thyroid Therapeutics / Egetis Emcitate carton are not this authorised EU pack. Today’s EU labelled oral door for peripheral thyrotoxicosis in MCT8 deficiency is Emcitate EMEA/H/C/005220.

Marketing authorisation holder: Rare Thyroid Therapeutics International AB, Klara Norra Kyrkogata 26, 111 22 Stockholm, Sweden (Egetis Therapeutics AB group). Company pipeline page states Emcitate is investigational and not FDA-approved in the United States.

Where this is taking place

Commercial labelled door today: European Union — EC-authorised Emcitate for peripheral thyrotoxicosis in MCT8 deficiency from birth; prescription only; start and supervise under a clinician experienced in rare genetic disorders. Germany: company confirms commercial availability from 1 May 2025. G-BA orphan benefit assessment procedure 2025-05-01-D-1191 completed with resolution 16 October 2025 — hint for a non-quantifiable additional benefit (English courtesy translation of the G-BA justification). Other EU4 / member-state pricing and reimbursement dossiers and timelines vary — authorised is not the same sentence as funded in every country.

United States (not labelled): FDA accepted the NDA with Priority Review; company PDUFA / decision target 28 September 2026. Emcitate is not FDA approved as of this draft. Documented pre-approval path: Expanded Access Program NCT05911399 — ClinicalTrials.gov status AVAILABLE; lead sponsor Rare Thyroid Therapeutics International AB; collaborators listed include Egetis Therapeutics AB and AnovoRx. Eligibility (registry): genetically confirmed MCT8 deficiency; treating physician judges benefit outweighs risk; sponsor approval for enrolment; patients eligible for an ongoing tiratricol trial are excluded. Honesty: AVAILABLE expanded access is a physician + sponsor process — not a walk-in pharmacy carton and not an FDA label.

Canada / other regulators: Emcitate authorisation not confirmed on sources used here. Do not import on your own. An EU pack is not a foreign Product Monograph.

Named research programmes (not commercial enrolment doors by themselves):

• Triac Trial I — NCT02060474 (COMPLETED) — Erasmus Medical Center–led Phase 2 open-label; 46 males; mean serum T3 4.97 → 1.82 nmol/L after 12 months (EMA overview / Lancet Diabetes & Endocrinology 2019).
• Triac Trial II — NCT02396459 (ACTIVE_NOT_RECRUITING) — young boys ≤30 months; company/pipeline: primary neurodevelopmental endpoints not met; secondary T3 reduction supportive.
• ReTRIACt — NCT05579327 (COMPLETED) — Phase 3 randomised withdrawal; company topline 14 Nov 2025: T3 rate-of-change primary p=0.034 (placebo vs continued tiratricol).
• EMC Cohort — van Geest et al., J Clin Endocrinol Metab 2022 (real-world long-term; up to ~6 years; n=67 on company/journal framing).
• EMC Survival — van der Most et al., ETA 2024 abstract / company 21 Aug 2024: HR 0.28 (95% CI 0.09–0.91) for all-cause mortality vs untreated in a retrospective international cohort (n=228) — abstract / company framing, not an FDA label claim.
• US EAP — NCT05911399 (AVAILABLE).

The practical door is a paediatric endocrinology / genetics / rare-thyroid team confirming SLC16A2 / MCT8 genetics and arranging the legal path that matches the home country.

Approval matrix

Access by country

• European Union (labelled): Ask a clinician experienced in rare genetic / MCT8 care about labelled Emcitate for peripheral thyrotoxicosis. Path: confirm MCT8 deficiency → pregnancy exclusion when relevant → individual T3-guided titration (SmPC) → national pharmacy / reimbursement rules. Germany has a commercial launch from 1 May 2025. Other member states: confirm local launch and funding with the treating centre. No list price or copay dollars in this article.

• United States: Emcitate is not FDA approved. Ask a paediatric endocrinology / genetics clinician whether Expanded Access NCT05911399 is appropriate while the NDA is under Priority Review (PDUFA target 28 Sep 2026). Path: genetic confirmation → treating physician judges benefit/risk → sponsor enrolment approval → follow registry and FDA expanded-access rules. Patients who can join an eligible clinical trial are generally directed there first. Do not import an EU pack as the care plan.

• Canada: Emcitate authorisation not confirmed. Ask the Canadian clinic what legal paths exist in Canada (including whether any Special Access Programme or other named-patient rule applies) while there is no Canadian Product Monograph.

• United Kingdom / Australia / Japan / Switzerland / other countries: Confirm your local regulator’s current status with the treating centre. Company managed-access statements are not a home licence. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, documented expanded access, or waiting for a home decision.

Who is eligible (from EMA SmPC + US EAP registry)

This is a peripheral thyrotoxicosis conversation — not a claim that tiratricol reverses all neurodevelopmental disability from brain hypothyroidism.

European Union (SmPC 4.1 / 4.2 / 4.3):

• Indication: Treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome), from birth.
• Form: 350 microgram dispersible tablets (scored; can be halved). Disperse in water; oral syringe or gastroenteral feeding tube.
• Starting titration (fact-only from SmPC): body weight ≥10 kg — start 350 µg daily, increase by 350 µg about every 2 weeks; body weight <10 kg — start 175 µg (half tablet) daily, increase by 175 µg about every 2 weeks. Titrate toward serum T3 below the midpoint of the age-normal range; give total daily dose in 1–3 divided doses. SmPC lists weight-based maximum µg/kg/day ceilings — the prescribing clinician uses the current SmPC.
• Lab honesty: Prefer LC/MS/MS for T3; tiratricol can cross-react on immunoassay.
• Contraindications: Hypersensitivity to tiratricol or excipients; hyperthyroidism for reasons other than MCT8 deficiency; pregnancy.
• Common adverse reactions (SmPC): hyperhidrosis (7%), diarrhoea (6%), irritability / anxiety / nightmares (2% each) — often at start or dose increase; usually transient.
• Supervision: Start and monitor under a physician experienced in rare genetic disorders such as MCT8 deficiency.

United States Expanded Access (NCT05911399 inclusion highlights):

• Genetically confirmed MCT8 deficiency.
• Treating physician opinion that potential benefits outweigh risks; signed consent; sponsor (RTT) approval for enrolment.
• Excludes patients eligible for tiratricol clinical trials; excludes pregnancy/nursing; other medical exclusions on the registry.

Not labelled / not claimed on sources confirmed for this draft:

• FDA or Health Canada marketing authorisation.
• Treating Emcitate as a cure for all MCT8 neurodevelopmental disability (Triac Trial II primary neurodevelopmental endpoints not met on company framing).
• Walk-in enrolment into COMPLETED / ACTIVE_NOT_RECRUITING research records.

How to access

If you are in a launched EU country (example: Germany):

1. Confirm genetically diagnosed MCT8 deficiency with a rare-disease endocrinology / genetics clinic.
2. Ask whether labelled Emcitate for peripheral thyrotoxicosis fits and how national reimbursement works.
3. Plan T3 monitoring (preferably LC/MS/MS), pregnancy exclusion when relevant, and titration follow-up.
4. Authorised is not funded — insurance and out-of-pocket paths vary; no prices in this article.

If you are in the United States:

1. Confirm MCT8 deficiency genetically with a paediatric endocrinology / genetics clinician.
2. Ask whether Expanded Access NCT05911399 is appropriate (and whether any open trial seat exists first).
3. Have the clinician follow the ClinicalTrials.gov / FDA expanded-access process and sponsor approval steps.
4. Watch the 28 September 2026 PDUFA target with the clinic — a target date is not an approval.

If you are in Canada or another country without a confirmed licence:

1. Ask the local specialist what legal special-access / named-patient options exist.
2. Do not mail-order or personally import an EU or EAP supply as the care plan.

Evidence snapshot

Triac Trial I — NCT02060474 (EMA overview + Lancet Diabetes & Endocrinology 2019; COMPLETED):

• Design: international, single-arm, open-label Phase 2 (no placebo comparator).
• Population: 46 children and adults with MCT8 deficiency.
• Result used at EU authorisation: mean serum T3 4.97 → 1.82 nmol/L after 12 months; supportive signals on heart rate, blood pressure, premature atrial contractions (EMA overview).

Triac Trial II — NCT02396459 (ACTIVE_NOT_RECRUITING; company/pipeline):

• Young boys ≤30 months (n=22 actual enrollment on CT.gov).
• Primary GMFM-88 / BSID-III gross-motor endpoints not met; durable T3 reduction on secondary framing.

ReTRIACt — NCT05579327 (COMPLETED; company topline 14 Nov 2025):

• Double-blind randomised withdrawal Phase 3 in males ≥4 years on stable tiratricol.
• PE1 T3 rate-of-change: ratio placebo/tiratricol 1.494 (95% CI 1.035–2.155); p=0.034. All 8 placebo patients had larger T3 rises than the 7 continuing tiratricol.

EMC Cohort (van Geest et al., JCEM 2022): long-term real-world tiratricol use (company: 67 patients, up to 6 years) with sustained T3 and peripheral marker framing.

EMC Survival (van der Most et al., ETA 2024 abstract / company 21 Aug 2024): retrospective n=228; treated vs untreated all-cause mortality HR 0.28 (95% CI 0.09–0.91) — observational; not an FDA label.

Honesty: Open-label and observational packages supported EU authorisation for peripheral thyrotoxicosis. They do not turn COMPLETED trials into walk-in enrolment, and they do not equal FDA approval.

How to talk with a doctor

Bring this page and ask a paediatric endocrinology / genetics / rare-thyroid clinician:

1. “We have genetically confirmed MCT8 deficiency. Is labelled EU Emcitate (or documented US Expanded Access NCT05911399) a fit for peripheral thyrotoxicosis?”
2. “How will we titrate dose and measure T3 (LC/MS/MS vs immunoassay)?”
3. “What are the pregnancy / hypermetabolic-symptom monitoring steps?”
4. If in the US: “What is the current status of NCT05911399, and how does the 28 Sep 2026 PDUFA date affect our plan?”
5. If outside a labelled country: “Has our regulator authorised Emcitate, or what legal special-access options exist?”

Who is involved (from primary sources)

• EU MAH: Rare Thyroid Therapeutics International AB, Stockholm (EMA EPAR / SmPC).
• Group / commercial: Egetis Therapeutics AB (publ), Nasdaq Stockholm: EGTX (company releases).
• EU research leadership cited on company launch: Professor Edward Visser and team, Erasmus University Medical Center, Rotterdam.
• Triac Trial I sponsor (CT.gov): Erasmus Medical Center (NCT02060474).
• Triac Trial II / ReTRIACt / US EAP sponsor (CT.gov): Rare Thyroid Therapeutics International AB; Egetis listed as collaborator where applicable.
• US EAP specialty pharmacy partner (company Dec 2023): AnovoRx.
• Company general contact (egetis.com): +46 8 679 72 10; info@egetis.com — company switchboard, not a verified patient hotline for EAP intake.

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted. No US patient phone is invented here — US EAP routing starts with the treating clinician and NCT05911399.

Sources

• EMA EPAR Emcitate — https://www.ema.europa.eu/en/medicines/human/EPAR/emcitate (Authorised; EC decision 12/02/2025; EMEA/H/C/005220)
• Emcitate EPAR Product Information / SmPC (350 µg dispersible tablets; indication from birth; posology; contraindications; ARs)
• Egetis pipeline / Emcitate page (EU approved; US investigational; Managed Access / US EAP framing; PDUFA 28 Sep 2026)
• Egetis MFN: Germany launch confirmation (5 May 2025; availability from 1 May 2025)
• Egetis MFN: FDA NDA acceptance + Priority Review (27 Mar 2026; PDUFA 28 Sep 2026)
• Egetis MFN: ReTRIACt topline (14 Nov 2025); EMC Survival abstract notice (21 Aug 2024); US EAP update (13 Dec 2023)
• ClinicalTrials.gov NCT02060474, NCT02396459, NCT05579327, NCT05911399
• Groeneweg et al., Lancet Diabetes Endocrinol 2019 (Triac Trial I) — DOI 10.1016/S2213-8587(19)30155-X
• van Geest et al., J Clin Endocrinol Metab 2022 (EMC Cohort) — DOI 10.1210/clinem/dgab750
• G-BA Nutzenbewertung Tiratricol / Emcitate procedure 1213 / D-1191; resolution 16 Oct 2025 (hint, non-quantifiable additional benefit)

Authorized is not funded. Not medical advice.

Not medical advice. Status: Unpublished. Do not publish.